evipedia.ai
← Back

Sh-Oligopeptide-9 for Hair Regrowth

Evidence Review created on 09/26/2026 using AI4L / Opus 5.5

Also known as: SH-Oligopeptide-9, sh-Oligopeptide-9, Synthetic Human Oligopeptide-9

Motivation

Sh-Oligopeptide-9 (Synthetic Human Oligopeptide-9) is a lab-made short protein fragment used as a cosmetic ingredient. It is produced by bacteria carrying a copy of the human gene for the body’s own opioid-like signaling molecules, which help regulate skin, nerves and cell growth. It appears in scalp serums, hair-fall masks and face creams, and draws interest from people hoping that signaling molecules applied to the scalp can reawaken thinning hair.

Its link to hair comes from two directions: a wave of peptide and “growth factor” scalp serums sold for thinning hair, and laboratory work showing that a sensor these signaling molecules act on sits in hair follicles and can switch them into their growth phase in mice. The same family of molecules also slows cell renewal in skin, so its biology cuts both ways.

This review examines what is known about Sh-Oligopeptide-9 applied to the scalp for hair regrowth: what the ingredient actually is, its proposed biology, the human evidence for benefit and harm, and how it sits alongside hair-loss treatments that have been tested in people.

Benefits - Risks - Protocol - Conclusion

Selected studies, reviews and expert commentary covering enkephalins (the body’s own opioid peptides), whose biology underlies Sh-Oligopeptide-9, and the hair-regrowth category in which it is marketed.

No relevant content on Sh-Oligopeptide-9, enkephalin-based hair products or topical cosmetic peptides for hair was found from Chris Kresser, Life Extension or Lifespan.io; Life Extension’s hair-loss articles focus on oral botanical formulas that lower dihydrotestosterone (the hormone that shrinks follicles), a different mechanism.

Grokipedia

No Grokipedia article on Sh-Oligopeptide-9 exists as of September 26, 2026.

Examine

No Examine article on Sh-Oligopeptide-9 exists as of September 26, 2026.

ConsumerLab

No ConsumerLab article on Sh-Oligopeptide-9 exists as of September 26, 2026.

Systematic Reviews

No systematic review or meta-analysis (a pooled analysis of trials) of Sh-Oligopeptide-9 itself exists; the paper below covers the forgone benefit of tested hair-loss treatments an untested serum can displace.

The claimed hair-regrowth effect of Sh-Oligopeptide-9 is not represented by any systematic review or meta-analysis.

Mechanism of Action

Sh-Oligopeptide-9 is defined in the INCI (International Nomenclature of Cosmetic Ingredients) dictionary, compiled by the Personal Care Products Council, a trade association whose member companies sell cosmetic ingredients and products, as an 11-amino-acid peptide made in Escherichia coli from a synthetic copy of the human proenkephalin (enkephalin precursor protein) gene (INCIDecoder ingredient entry). No sequence is published, but its listed amino acids include those of the enkephalin core (the body’s own opioid peptides), so any hair effect would run through enkephalin targets:

  • Pro-growth pathway: Enkephalins activate the δ-opioid receptor, which is abundant in the outer root sheath (the follicle’s outer cell layer) during anagen; a synthetic δ-opioid activator sped anagen onset in mice via Wnt/β-catenin signaling (a pathway that switches on follicle stem cells) (Zheng et al., 2021).
  • Anti-growth pathway: Met-enkephalin (methionine-enkephalin) also acts as “opioid growth factor” on its own receptor, braking cell division; injected Met-enkephalin cut mouse outer-skin DNA synthesis (cell-copying activity) by 37–46% (Wilson et al., 2000).
  • Pharmacology: At an estimated 1,200–1,400 daltons (units of molecular mass), it exceeds the roughly 500-dalton ceiling for passive skin penetration (Bos & Meinardi, 2000). Enkephalins are cleaved by aminopeptidases (enzymes that clip amino acids off peptide ends), with an in-vitro (test-tube) plasma half-life (time for half to be broken down) near 13 minutes (Mosnaim et al., 1988); no cytochrome P450 (liver drug-metabolizing) enzyme is involved. Receptor selectivity and tissue distribution of the cosmetic peptide itself are uncharacterized.

Historical Context & Evolution

The enkephalins were identified in 1975 as the brain’s own opioid peptides and were first studied for pain control (Hughes et al., 1975). Over the following decades, work by Zagon and McLaughlin recast Met-enkephalin as a growth regulator that slows cell renewal in skin and other tissues (Wilson et al., 2000). Later studies showed that human skin makes proenkephalin itself, with enkephalins in the follicle’s outer root sheath and production rising after ultraviolet light or immune triggers (Slominski et al., 2011).

The “sh-“ prefix (synthetic human) entered the cosmetic ingredient dictionary as recombinant (made by engineered microbes) human growth factors, such as Sh-Oligopeptide-1, an analog of epidermal growth factor (a skin-cell growth signal), moved into skin care. Sh-Oligopeptide-9 was registered with humectant (water-binding), skin-conditioning and skin-protecting functions rather than a hair-growth function, and appears mainly in Korean face products and a few scalp products. Its association with hair regrowth appears to come from multi-peptide “growth factor” hair serums and possibly from confusion with the similarly named Sh-Polypeptide-9, a blood-vessel growth factor analog.

A 2023 analysis argued that cosmetic Sh-Oligopeptide-1 had no demonstrated bioactivity and that clinical trials of it lacked a laboratory basis (Martínez-Carpio, 2023); no published rebuttal from manufacturers was located. The 2021 finding that δ-opioid receptor activation promotes mouse hair growth is the newest mechanistic input (Zheng et al., 2021). No study has tested Sh-Oligopeptide-9 itself on follicles, so its standing remains open.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no controlled human trial of Sh-Oligopeptide-9 has measured any hair outcome, and the only relevant data are animal and cell-culture studies of related opioid-receptor activators.

Medium 🟩 🟩

No benefit reaches Medium: not a single human trial or observational dataset has recorded hair outcomes after Sh-Oligopeptide-9 application.

Low 🟩

Speculative 🟨

Growth-Phase Induction via δ-Opioid Receptor ⚠️ Conflicted

A synthetic δ-opioid receptor activator sped anagen onset in mice (Zheng et al., 2021), but Met-enkephalin slows mouse outer-skin cell division (Wilson et al., 2000). Animal data only. Net: effect on human follicles unknown.

Scalp and Hair-Shaft Moisture ⭕️ Not Central to Hair Regrowth

Ingredient dictionaries list Sh-Oligopeptide-9 as a humectant (water-binding agent) and skin conditioner. This bears on scalp comfort and hair-shaft feel, not follicle regrowth. No controlled study exists; the basis is ingredient classification only.

Scalp Skin Repair ⭕️ Not Central to Hair Regrowth

Mice lacking the δ-opioid receptor healed burns about 2 days slower (Bigliardi-Qi et al., 2006). This bears on scalp barrier recovery, not regrowth. The basis is animal and mechanistic only.

Benefit-Modifying Factors

  • Genetic polymorphisms: Pattern hair loss is strongly inherited through the AR gene (androgen receptor, the testosterone-sensing protein) and many other variants (Heilmann-Heimbach et al., 2017); enkephalin signaling does not target this androgen pathway. OPRD1 (the δ-opioid receptor gene) variants are unstudied.
  • Baseline biomarkers: Low ferritin (iron stores), thyroid dysfunction or vitamin D deficiency drive shedding that a scalp peptide does not correct, and would mask or override any serum effect until addressed.
  • Sex: No sex-specific data exist. Women more often rely on cosmetic serums because hormone-blocking drugs are restricted in pregnancy-capable women; frontal hairline recession in men responds least to topical agents generally.
  • Pre-existing conditions: Any benefit is plausible only in non-scarring loss with surviving follicles, such as androgenetic alopecia (hormone-driven pattern hair loss) or telogen effluvium (stress-triggered shedding); scarring alopecias (inflammatory conditions that destroy follicles) and alopecia areata (immune attack on follicles) have different drivers.
  • Age: Younger adults with early follicle shrinkage retain more recoverable follicles; adults at the older end of the target range typically have advanced shrinkage and fewer follicles any topical agent could rescue.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no trial or surveillance system has recorded adverse events from Sh-Oligopeptide-9, so no replicated human adverse-event data exist.

Medium 🟥 🟥

No risk reaches Medium: neither a single trial nor observational data report adverse events attributable to Sh-Oligopeptide-9.

Low 🟥

Contact Dermatitis from the Product Formula

Leave-on scalp products can cause allergic or irritant contact dermatitis (inflamed, itchy skin). In skin-allergy patch testing, hair-product reactions were driven by dyes, preservatives and surfactants (detergents) (Warshaw et al., 2022). The peptide itself, estimated at 1,200–1,400 daltons, is an unlikely allergy trigger. Evidence is indirect.

Magnitude: 9.0% of 38,775 North American patients patch-tested for suspected dermatitis had reactions linked to hair care products; no figure exists for Sh-Oligopeptide-9 products specifically.

Forgone Benefit of Tested Hair-Loss Treatments

Relying on an untested serum instead of tested treatment allows androgenetic alopecia to progress. In a trial run by finasteride maker Merck, placebo-treated men lost hair over 2 years while treated men gained (Kaufman et al., 1998). Shrunken follicles may not recover. Evidence is indirect: no study tracked serum users.

Magnitude: Finasteride-treated men had 107 more hairs than placebo at 1 year and 138 more at 2 years in a 5.1 cm² crown area (baseline 876 hairs), a gap partly reflecting continued loss on placebo.

Speculative 🟨

Slowed Follicle Cell Division

Met-enkephalin acting on its growth-braking receptor cut mouse outer-skin DNA synthesis by 37–46% (Wilson et al., 2000). If Sh-Oligopeptide-9 were active, follicle growth could slow. Basis is animal and mechanistic only.

Systemic Opioid Effects

Enkephalins act on opioid receptors, so sedation is a theoretical concern. Size limits skin passage (Bos & Meinardi, 2000) and blood enzymes degrade enkephalins within minutes (Mosnaim et al., 1988). Basis: mechanistic only.

Residual Bacterial Endotoxin

Peptides made in Escherichia coli can carry endotoxin (bacterial cell-wall fragments that trigger inflammation) if purification is poor. This matters most on needled or broken skin. Basis: mechanistic only, no reports.

Risk-Modifying Factors

  • Genetic polymorphisms: No variant has been studied with this ingredient. FLG (filaggrin, a skin-barrier protein gene) loss-of-function variants weaken the skin barrier and are linked to contact sensitization, plausibly raising dermatitis risk.
  • Baseline biomarkers: No blood marker predicts reactions; a history of positive patch tests, especially to methylisothiazolinone (a preservative) or fragrance, marks higher dermatitis risk.
  • Sex: Women made up 79.9% of patients with hair-product-related dermatitis in North American patch-test data (Warshaw et al., 2022), reflecting heavier product use rather than proven biological susceptibility.
  • Pre-existing conditions: Atopic dermatitis (eczema), seborrheic dermatitis (flaky, greasy scalp inflammation) or psoriasis impair the scalp barrier, increasing penetration and irritation; psoriatic skin already shows raised enkephalin levels (Slominski et al., 2011).
  • Age: Older scalp skin is thinner and drier, raising irritation risk; older adults with advanced loss also lose more from delaying tested treatment.

Key Interactions & Contraindications

  • Topical minoxidil (Rogaine): Monitor. No pharmacological interaction is known, but layering adds vehicle irritation because minoxidil solutions often contain propylene glycol (a solvent and common irritant); consequence is scalp dermatitis. Applying the two products at different times of day limits this.
  • Opioid antagonists (opioid receptor blockers; naltrexone, naloxone): Theoretical, low relevance. These would cancel any δ- or μ-opioid (the main painkiller receptor) action of the peptide, removing its proposed mechanism; no clinical harm expected. No mitigating action is needed.
  • Topical retinoids (vitamin A–derived skin drugs; tretinoin, adapalene): Caution. These thin the outer barrier, increasing peptide and preservative penetration and raising irritation and dermatitis risk. Separating applications by several hours and starting on alternate days reduces this.
  • 5α-reductase inhibitors (drugs blocking testosterone’s conversion to dihydrotestosterone, the hormone that shrinks follicles; finasteride, dutasteride): No interaction expected. These oral drugs act by a separate route and target; they are commonly combined with topical serums.
  • Over-the-counter antifungal shampoo (ketoconazole 1%): Monitor. Additive scalp dryness and irritation are possible; consequence is flaking and itch. Applying the serum on non-shampoo days, or after the scalp has fully dried, limits overlap.
  • Over-the-counter enkephalinase inhibitor (a drug slowing enkephalin breakdown; racecadotril): Theoretical. This oral antidiarrheal is sold without prescription in some European countries; no clinically relevant consequence for a topical peptide is expected. Monitoring for unusual drowsiness is the only step.
  • Topical hair supplements (caffeine, rosemary oil, copper peptide GHK-Cu, a copper-binding tripeptide): Monitor; additive. These also claim hair benefit, so any effect would be additive, as would irritation risk. Introducing one product at a time, 2–4 weeks apart, identifies the cause of any reaction.
  • Oral biotin supplements (above 5 mg/day): Monitor. No interaction with the peptide, but high-dose biotin distorts thyroid and other lab results used in hair-loss workups, causing misdiagnosis. Pausing biotin 2–3 days before blood tests avoids this.
  • Microneedling: Caution. Needling bypasses the skin barrier, increasing penetration of peptide, preservatives and any endotoxin; consequences include irritation, infection and foreign-body skin reactions. Using only sterile products and waiting 24 hours after needling deeper than 0.5 mm reduces risk.

Populations who should avoid Sh-Oligopeptide-9:

  • Known allergy to any product ingredient (positive patch test or prior reaction to the formula)
  • Active scalp dermatitis, psoriasis flare, scalp infection or open wounds (any severity)
  • Pregnancy (all trimesters) and breastfeeding, for lack of safety data
  • Children and adolescents under 18 years, for lack of data
  • Scarring alopecia (e.g., lichen planopilaris, frontal fibrosing alopecia, both inflammatory follicle-destroying conditions) or sudden patchy loss suggesting alopecia areata, as sole treatment, since these need medical diagnosis

Risk Mitigation Strategies

  • Forearm test before scalp use: Applying the product twice daily to the inner forearm for 7 days (repeated open application test) before scalp use screens for contact dermatitis.
  • Allergen-conscious formula: Formulas free of methylisothiazolinone and added fragrance avoid two leading hair-product allergens, reducing contact dermatitis risk.
  • Tested therapy kept in place: Adding the serum to minoxidil or finasteride, rather than substituting it, removes the forgone-benefit risk while hair loss continues to progress.
  • Six-month checkpoint: Standardized photographs at baseline and 6 months give an objective stop rule, limiting months lost to an ineffective product.
  • Intact-skin application: Applying only to unbroken scalp, and waiting 24 hours after microneedling deeper than 0.5 mm, limits endotoxin and preservative penetration, reducing irritation and foreign-body reaction risk.
  • Shedding watch: Shedding clearly above one’s own baseline beyond 8–12 weeks of use is a stop signal, addressing the theoretical growth-braking effect.

Therapeutic Protocol

  • No standardized protocol: No clinician, trial or expert group has published a Sh-Oligopeptide-9 hair protocol, and labels rarely disclose its concentration. The points below reflect how multi-peptide scalp serums containing it are labeled for use.
  • Typical label regimen: A few drops to about 1 mL applied to a clean, dry scalp once or twice daily, massaged in and left on without rinsing.
  • Approach 1, stand-alone cosmetic: Used alone by people avoiding drugs, typically promoted by the product brands themselves; this approach has no hair-outcome data for Sh-Oligopeptide-9.
  • Approach 2, add-on to tested treatment: Layered with minoxidil or finasteride, whose regrowth effects were confirmed in a meta-analysis (Adil & Godwin, 2017); the serum’s added contribution is untested.
  • Approach 3, microneedling-assisted delivery: Growth-factor solutions applied with microneedling improved hair parameters in low-quality studies reviewed by Robert English of Perfect Hair Health (English et al., 2022); none used Sh-Oligopeptide-9.
  • Time of day: No timing data exist. Evening application after the last wash of the day allows several hours of undisturbed contact before sweating or rinsing.
  • Half-life: Enkephalins are broken down in human plasma with an in-vitro half-life near 13 minutes (Mosnaim et al., 1988); residence time on the scalp surface is unmeasured.
  • Single vs. split doses: Labels specify once or twice daily application; no data compare them. Twice-daily use doubles exposure to preservatives and fragrance.
  • Genetic factors: No gene variant is known to alter response or dose. A strong family history of pattern loss implies faster progression, raising the cost of an ineffective choice.
  • Sex differences: No sex-specific dosing or response data exist. Women’s diffuse thinning and men’s crown and hairline loss differ in pattern, and finasteride is avoided in women who could become pregnant.
  • Age: Older users, with more advanced follicle shrinkage and thinner scalp skin, have less regrowable reserve and higher irritation risk; no age-specific data exist.
  • Baseline biomarkers: No marker predicts response. Correcting low ferritin, thyroid dysfunction or vitamin D deficiency addresses shedding causes a scalp peptide cannot.
  • Pre-existing conditions: Active seborrheic dermatitis or psoriasis raises irritation risk and confounds shedding assessment; scarring alopecias and alopecia areata are medical conditions outside cosmetic scope.

Discontinuation & Cycling

  • Duration: No defined course exists; products are labeled for continuous use. A time-limited trial of about 6 months matches the hair-cycle timescale used to judge tested treatments.
  • Withdrawal effects: None known or expected; no dependence mechanism has been described for topical enkephalin-derived peptides.
  • Tapering: Not applicable; the product can be stopped abruptly.
  • Loss of gains: If any benefit exists, it would likely fade after stopping, as regrowth from minoxidil does; no Sh-Oligopeptide-9 data exist.
  • Cycling: No evidence supports cycling. Receptor tolerance with repeated opioid exposure is described for pain drugs but untested for this peptide.

Sourcing and Quality

  • Identity: The INCI definition specifies 11 amino acids from the human proenkephalin gene, expressed in Escherichia coli, but no public sequence exists, so products cannot be compared by composition.
  • Concentration: Rarely disclosed. Under US and EU labeling rules, ingredients at or below 1% may be listed in any order after the rest, and peptides usually appear near the end of ingredient lists.
  • Confusable names: Sh-Polypeptide-9 (a blood-vessel growth factor analog) and Sh-Oligopeptide-1 (an epidermal growth factor analog) are different ingredients; checking the exact name on the label avoids mistaking them.
  • Quality markers: Supplier certificates of analysis, endotoxin testing, and airless or opaque packaging (peptides degrade with air, light and heat) are the available quality signals; no independent laboratory tests this ingredient.
  • Brands: Appears mainly in Korean skin-care lines (Mizon, Sungboon Editor) and a few scalp products such as Placenta Xivitae Regenerating Hair-fall Prevention Mask (product list); no brand has published hair data.

Practical Considerations

  • Time to effect: Hair cycles are slow; tested treatments needed months to a year to separate from placebo (Kaufman et al., 1998), so judging any scalp serum takes at least 6 months.
  • Common pitfalls: Confusing Sh-Oligopeptide-9 with Sh-Polypeptide-9; treating label words such as “growth factor” or “regrowth” as evidence; stopping tested treatments; judging results after weeks; and misreading normal seasonal shedding as failure or success.
  • Regulatory status: A cosmetic ingredient in the EU and US. In the US, a product claiming to restore hair growth is legally a drug requiring FDA (US Food and Drug Administration) approval (FDA guidance); no Sh-Oligopeptide-9 product holds such approval.
  • Cost and accessibility: Not exceptionally expensive and widely sold online. Insurers and national health systems generally pay for neither cosmetic serums nor pattern hair-loss drugs, so payer incentives do not systematically favor either option.

Interaction with Foundational Habits

  • Sleep: None direct. No sleep effect is expected from a topical peptide. Letting the scalp dry for about 30 minutes after evening application limits transfer to pillowcases; chronic sleep loss acts on hair indirectly through stress-related shedding.
  • Nutrition: Indirect. Protein, iron, zinc and vitamin D deficits cause shedding that no topical peptide corrects; adequate protein (about 1.2 g/kg daily for active adults) and iron-rich foods address causes the serum cannot.
  • Exercise: None direct. Sweat and post-workout washing dilute or remove leave-on serums, so applying after the post-exercise shower preserves contact time. Exercise raises the body’s own opioid peptides, with no known effect on hair.
  • Stress management: Indirect. Skin makes more proenkephalin under stressors such as ultraviolet light (Slominski et al., 2011), and severe stress triggers telogen effluvium; stress reduction addresses a shedding cause independent of the serum.

Monitoring Protocol & Defining Success

Baseline (before starting): Standardized scalp photographs of the crown, part and hairline (same lighting, camera distance and hair state) and, where available, a phototrichogram (magnified scalp imaging that counts hairs per cm²) establish a reference. Blood tests screen for common non-hormonal causes of shedding, namely iron deficiency, thyroid disease and low vitamin D, which no topical peptide addresses. A 7-day repeated open application test on the inner forearm screens for allergy to the product.

Ongoing monitoring: Photographs and density counts are repeated at 3 months and 6 months, then every 6 months while use continues. Blood tests are repeated only if baseline values were abnormal or shedding worsens. New scalp redness, itching or scaling at any point is a signal to stop and reassess.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Hair density (phototrichogram) No established target; track change from own baseline Objective regrowth readout Same marked scalp site each time; compare at 6 months or later; best paired with photographs
Standardized scalp photographs No established target; track change from own baseline Visible coverage change Same lighting, camera and hair state (wet or dry); pair with density count
Ferritin 70–150 ng/mL Iron stores; low levels linked to shedding Ferritin is the iron-storage protein; conventional range roughly 15–150 ng/mL (women) and 30–400 ng/mL (men); rises with inflammation, so pair with CRP (C-reactive protein, an inflammation marker); fasting not required
TSH 0.5–2.5 mIU/L Screens thyroid-related shedding TSH (thyroid-stimulating hormone, the pituitary signal to the thyroid); conventional range about 0.4–4.5 mIU/L; morning draw; pair with free T4 (the main thyroid hormone); pause high-dose biotin 2–3 days before
25-hydroxyvitamin D 40–60 ng/mL Low levels associated with hair loss The circulating storage form of vitamin D; conventional sufficiency threshold 30 ng/mL; any time of day
Zinc (plasma) 90–120 µg/dL Deficiency causes shedding Conventional range about 60–120 µg/dL; morning fasting sample preferred because levels fall after meals

Qualitative markers:

  • Shedding: hairs on pillow, in the shower drain and on the brush, counted on standardized wash days
  • Scalp comfort: itch, redness, flaking or stinging after application
  • Hair feel: softness, breakage and shaft thickness to the touch
  • Styling coverage: how easily thinning areas can be concealed

Emerging Research

  • Peptide serum versus minoxidil: A double-blind randomized trial (chance-assigned, with neither participants nor investigators knowing assignments) in Thailand compares a peptide factor hair serum with 2% minoxidil in 80 adults with androgenetic alopecia over 24 weeks, primary endpoint hair density (NCT07536100). Whether the serum contains Sh-Oligopeptide-9 is not disclosed.
  • Growth-factor serum for chemotherapy hair loss: A completed early-phase single-arm study (NCT04554732) found a keratinocyte growth factor (a skin-cell growth signal) hair serum did not prevent chemotherapy-induced hair loss in any of 20 assessed women (Mann et al., 2026); it did not use Sh-Oligopeptide-9, but shows a topical growth-factor serum failing when tested.
  • δ-opioid receptor activators for hair: Zheng et al., 2021 proposed developing δ-opioid receptor activators for hair loss; a human trial of any enkephalin-pathway agent on hair would directly test the pro-growth case.
  • Growth-braking opioid signaling: Met-enkephalin’s suppression of skin cell division (Wilson et al., 2000), if confirmed in human follicle cultures with enkephalin peptides, would weaken the case for Sh-Oligopeptide-9 on hair.
  • Bioactivity testing of sh-peptides: Martínez-Carpio, 2023 argued that cosmetic Sh-Oligopeptide-1 lacks proven bioactivity; the same receptor-activation and stability testing applied to Sh-Oligopeptide-9 would show whether it signals at all or only binds water.
  • Benchmark from growth-factor injections: A 2026 meta-analysis found autologous (patient-derived) growth-factor injections increased hair density, with high risk of bias (Alali et al., 2026); it sets the evidence bar topical peptides would need to meet.

Conclusion

Sh-Oligopeptide-9 is a lab-made fragment of one of the body’s own opioid-like signaling molecules, sold as a moisturizing and skin-conditioning cosmetic ingredient. For hair regrowth, no human study of any kind has tested it. The case for a hair effect rests on an indirect chain: these signaling molecules act on a cell sensor that is plentiful in growing hair follicles, and switching that sensor on pushed mouse follicles into their growth phase. The same family of molecules also acts as a brake on skin cell renewal in mice, so even the direction of any effect is unsettled. Whether the cosmetic peptide passes through the scalp, or survives skin enzymes long enough to act, is also unknown.

The risks appear small and belong mostly to the product formula, such as preservatives that can inflame the scalp. For people actively working to keep their hair, the larger consideration is time: pattern hair loss keeps progressing, and months spent on an untested serum are months without treatments that have trial support.

Much of what is written about this ingredient comes from parties with a commercial stake. The ingredient definitions are compiled by a cosmetics trade association whose members sell such products, the key mouse hair-growth study came from authors at a biotechnology company, and product claims come from sellers. On the other side, the main trial on untreated hair loss was run by the tested drug’s maker. Taken together, the evidence places Sh-Oligopeptide-9 among untested hair-regrowth ideas rather than tested ones.

Top - Benefits - Risks - Protocol